Serotonin mechanisms in fentanyl-induced respiratory depression
Project Number1R01DA061320-01
Contact PI/Project LeaderLEVITT, ERICA SAWYER
Awardee OrganizationUNIVERSITY OF MICHIGAN AT ANN ARBOR
Description
Abstract Text
Project Summary
Fentanyl and other ultrapotent synthetic opioids cause respiratory depression, a potentially fatal acute toxic
effect that is mediated by activation of mu opioid receptors. Naloxone, an antagonist of mu opioid receptors,
can reverse fentanyl-induced respiratory depression, but must compete with ultrapotent opioids for receptor
binding. A respiratory stimulant that acts independently of opioid receptors would be an appealing approach to
combat ultrapotent synthetic opioid poisoning. Serotonin generally provides a net stimulatory effect on
breathing due, in part, to 5HT2A/2C receptors in respiratory controlling areas in the brainstem. In addition, the
emerging interest in serotonergic psychedelics for the treatment of various neuropsychiatric disorders,
including opioid use disorder, has led to renewed interest in development of serotonin agents, particularly
targeting the 5HT2A receptor. Activation of 5HT2A receptors in the dorsolateral pons can counter opioid-
induced respiratory depression and microinjection studies implicate medullary raphe neurons, which produce
serotonin, in opioid-induced respiratory depression, but mechanisms for these effects are unknown. The
overall goal of this proposal is to fill a major void in our understanding of serotonergic mechanisms in fentanyl-
induced respiratory depression. We hypothesize that fentanyl interferes with serotonin mediated mechanisms
that support breathing, which can be reversed by activation of 5HT2A receptors. We will test this hypothesis at
the cellular, circuit and whole animal level using approaches that selectively identify and modulate serotonin
neurons. Aim 1 will determine the effect of fentanyl on medullary raphe serotonin neuron activity mediated by
pre- and/or post-synaptic opioid receptors by recording from genetically labeled serotonin neurons contained in
acute brain slices. The role of post-synaptic opioid receptors on serotonin neurons in fentanyl-induced
respiratory depression will be determined in awake behaving mice. Aim 2 will determine the cellular and
synaptic mechanisms by which 5HT2A receptors and endogenous serotonin neurons counter opioid inhibition
of dorsolateral pontine neurons using ex vivo electrophysiology and a unique arterially perfused
pontomedullary circuit preparation. Aim 3 will determine the effect of systemic 5HT2A/2C agonists on fentanyl-
induced respiratory depression alone and in combination with a sub-therapeutic dose of naloxone in awake
behaving mice. Together, this R01 project will improve our understanding of serotonin mechanisms in fentanyl-
induced respiratory depression that will inform how to best leverage the serotonin system to counter fentanyl
toxicity in future studies.
Public Health Relevance Statement
Project Narrative
Fentanyl and other ultrapotent opioids interfere with the normal functioning of brainstem circuitry that controls
breathing leading to potentially fatal respiratory depression. The proposed studies will provide mechanistic
details on serotonergic mechanisms involved in respiratory depression to inform how the serotonin system
could be leveraged to combat acute fentanyl toxicity. The outcomes of this research will advance our
understanding of the pontomedullary circuitry that controls breathing and provide timely assessment of the
safety of co-use of drugs activating 5HT2A receptors, such as serotonergic psychedelics, with fentanyl.
No Sub Projects information available for 1R01DA061320-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01DA061320-01
Patents
No Patents information available for 1R01DA061320-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01DA061320-01
Clinical Studies
No Clinical Studies information available for 1R01DA061320-01
News and More
Related News Releases
No news release information available for 1R01DA061320-01
History
No Historical information available for 1R01DA061320-01
Similar Projects
No Similar Projects information available for 1R01DA061320-01